AHA Scientific Sessions 2025
VESALIUS-CV trial: Evolocumab effective in patients with no prior MI or stroke
Treatment with the PCSK9 inhibitor evolocumab cut the risk of coronary heart disease death, heart attack or ischaemic stroke by a quarter in adults with atherosclerotic cardiovascular disease (ASCVD) and no history of heart attack or stroke, suggest new study results. Findings from the VESALIUS-CV…
read more »
CORALreef Lipids: Enlicitide pill lowers LDL-C by up to 60% in at-risk patients
The oral PCSK9 inhibitor, enlicitide, lowered low density-lipoprotein cholesterol (LDL-C) by up to 60% in patients who had experienced a heart attack or stroke, or were at high risk of one, revealed new study results. Findings from the CORALreef Lipids trial of 2,912 adults were…
read more »
FOURIER: Markedly lowering LDL-C levels cuts MACE in patients after stroke
Lowering low-density lipoprotein cholesterol levels with evolocumab in patients with prior ischaemic stroke significantly reduced the risk of a future major adverse cardiovascular event (MACE), according to new findings. The results of a secondary analysis of patients enrolled in the FOURIER and FOURIER-Open Label Extension…
read more »
CAVIAR: Alirocumab plus statin may help lower LDL-C after heart transplant
The PCSK9 inhibitor, alirocumab, when given with a statin more than halved levels of low-density lipoprotein cholesterol (LDL-C) in patients following a heart transplant compared with placebo and statins, showed a new study. The results of the CAVIAR (Cardiac Allograft Vasculopathy Inhibition with AliRocumab) trial…
read more »
